| 36.7 -0.24 (-0.65%) | 09-28 15:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.86  |
1-year : | 75.69 |
| Resists | First : | 53.82 |
Second : | 64.8 |
| Pivot price | 48.7 |
|||
| Supports | First : | 36.04 |
Second : | 29.99 |
| MAs | MA(5) : | 37.46 |
MA(20) : | 51.55 |
| MA(100) : | 57.99 |
MA(250) : | 50.83 |
|
| MACD | MACD : | -6.6 |
Signal : | -4.8 |
| %K %D | K(14,3) : | 4.7 |
D(3) : | 4.7 |
| RSI | RSI(14): 16.6 |
|||
| 52-week | High : | 72.66 | Low : | 36.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XENE ] has closed above bottom band by 20.1%. Bollinger Bands are 342.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.35 - 38.54 | 38.54 - 38.69 |
| Low: | 35.99 - 36.24 | 36.24 - 36.44 |
| Close: | 36.59 - 36.97 | 36.97 - 37.28 |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Thu, 24 Sep 2026
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia
Wed, 23 Sep 2026
XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) For Potential Securities Fraud - accessnewswire.com
Wed, 23 Sep 2026
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - businesswire.com
Tue, 22 Sep 2026
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Yahoo Finance
Tue, 22 Sep 2026
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 107.6 (%) |
| Shares Short | 5,670 (K) |
| Shares Short P.Month | 6,340 (K) |
| EPS | -4.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | -43.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.64 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -338 (M) |
| Levered Free Cash Flow | -204 (M) |
| PE Ratio | -7.74 |
| PEG Ratio | 0 |
| Price to Book value | 2.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|